[SCHEDULE 13G] REVIVA PHARMACEUTICALS HOLDINGS, INC. SEC Filing

Rhea-AI Filing Summary

683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman report beneficial ownership of 5,435,000 shares of Reviva Pharmaceuticals Holdings, Inc., representing approximately 5.36% of the company’s common stock on a fully-diluted basis as of September 29, 2025. The stake comprises 450,000 issued shares and 4,985,000 currently exercisable warrants, and the reporting persons note shared voting and dispositive power.

The filing states the position is not held to influence control of the issuer and lists reporting addresses in New York and Delaware organizational details.

Positive

• Material passive disclosure: Reporting Persons transparently disclose a 5.36% beneficial position, meeting SEC transparency standards.
• Warrants detailed: Identification of 4,985,000 currently exercisable warrants clarifies potential dilution and conversion timing.
• Certification of passive intent: The filing explicitly states the securities are not held to influence control, reducing immediate takeover concerns.

Negative

• None.

Insights

Financial Analyst

TL;DR: A passive but material 5.36% equity stake primarily via exercisable warrants could affect dilution and market perception.

The filing discloses a 5.36% beneficial ownership calculated using 96,337,119 outstanding shares plus 4,985,000 warrant shares, with 450,000 shares held outright and the balance via exercisable warrants. From an investor perspective, the stake is material enough to warrant monitoring for future warrant exercises that would increase share count and potentially pressure the share price or signal confidence if exercised. The certification indicates the stake is not intended to change control, consistent with an investment-adviser/partner holding.

Corporate Governance Expert

TL;DR: Reporting is complete and standard for Schedule 13G; governance impact appears limited absent coordinated group action.

The Schedule 13G is filed under passive investor rules and identifies shared voting/dispositive power among an investment manager, its fund, and an individual. The disclosure of shared powers and the certification that the position is not meant to influence control satisfy typical governance transparency requirements. Investors should note the existence of exercisable warrants that convert economic exposure into voting shares upon exercise, but there is no stated intent to form a control group or to pursue board influence in this filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76152G100

(CUSIP Number)

09/22/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 76152G100

1

Names of Reporting Persons

683 CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,435,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,435,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,435,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.36 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 76152G100

1

Names of Reporting Persons

683 CAPITAL PARTNERS, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,435,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,435,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,435,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.36 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 76152G100

1

Names of Reporting Persons

Zweiman Ari

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,435,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,435,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,435,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.36 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
(b)	Address of issuer's principal executive offices: 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014
Item 2.
(a)	Name of person filing: 683 Capital Management, LLC 683 Capital Partners, LP Ari Zweiman Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
(c)	Citizenship: 683 Capital Management, LLC - DELAWARE 683 Capital Partners, LP - DELAWARE Ari Zweiman - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 76152G100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of September 29, 2025, 683 Capital Partners, LP beneficially owned (i) 450,000 shares of Common Stock and (ii) warrants to purchase 4,985,000 shares of Common Stock which are currently exercisable. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the (i) 450,000 shares of Common Stock and (ii) warrants to purchase 4,985,000 shares of Common Stock which are currently exercisable beneficially owned by 683 Capital Partners, LP. Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned (i) 450,000 shares of Common Stock and (ii) warrants to purchase 4,985,000 shares of Common Stock which are currently exercisable beneficially owned by 683 Capital Management, LLC. The following percentage is based on 96,337,119 shares of Common Stock outstanding following the completion of the offering described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) filed on September 19, 2025 plus 4,985,000 shares of Common Stock issuable upon exercise of currently exercisable warrants held by the Reporting Persons. As of September 29, 2025, the Reporting Persons may be deemed to have beneficially owned 5,435,000 shares of Common Stock, constituting approximately 5.36% of the outstanding shares of Common Stock.
(b)	Percent of class: 5.36%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

683 CAPITAL MANAGEMENT, LLC

Signature:	/s/ Ari Zweiman
Name/Title:	Ari Zweiman, Managing Member
Date:	09/29/2025

683 CAPITAL PARTNERS, LP

Signature:	/s/ Ari Zweiman
Name/Title:	Ari Zweiman, Authorized Person
Date:	09/29/2025

Zweiman Ari

Signature:	/s/ Ari Zweiman
Name/Title:	Ari Zweiman, Self
Date:	09/29/2025

FAQ

What stake in Reviva Pharmaceuticals (RVPH) do the reporting persons hold?

They beneficially own 5,435,000 shares of common stock on a fully-diluted basis, representing approximately 5.36% of the class as of September 29, 2025.

How is the 5.36% ownership composed for RVPH?

The position comprises 450,000 issued shares and 4,985,000 currently exercisable warrants, per the Schedule 13G.

Does the filing indicate intent to influence control of RVPH?

No. The certification states the securities were not acquired and are not held to change or influence control of the issuer.

Who are the reporting persons for this Schedule 13G for RVPH?

The reporting persons are 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman (individual).

What is the effective date of the ownership information in the filing?

The ownership is reported as of September 29, 2025.